1
|
Contreras-Salinas H, Orozco-Ceja V, Romero-López MS, Barajas-Virgen MY, Baiza-Durán LM, Rodríguez-Herrera LY. Ocular Cyclopentolate: A Mini Review Concerning Its Benefits and Risks. Clin Ophthalmol 2022; 16:3753-3762. [PMID: 36411874 PMCID: PMC9675330 DOI: 10.2147/opth.s388982] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Accepted: 10/28/2022] [Indexed: 07/30/2023] Open
Abstract
Cycloplegic and mydriatic agents are essential in ophthalmological clinical practice since they provide the means for diagnosing and treating certain eye conditions. In addition, cyclopentolate has proven to possess certain benefits compared to other available cycloplegics and mydriatics. Still, the incidence of some adverse drug reactions related to this drug, especially in susceptible patients, has created interest in reviewing the literature about the benefits and risks of using cyclopentolate. A literature search was conducted in Medline/PubMed and Google Scholar, focusing on identifying cyclopentolate's benefits and risks; the most important benefit was its usefulness for evaluating refractive errors, especially for hyperopic children, pseudomyopia, anterior uveitis, treatment of childhood myopia, idiopathic vision loss, and during examinations before refractive surgery, with particular advantages compared to other cycloplegics. While the risks were divided into local adverse drug reactions such as burning sensation, photophobia, hyperemia, punctate keratitis, synechiae, and blurred vision, which are relatively frequent but mild and temporary; and systemic adverse drug reactions such as language problems, visual or tactile hallucinations and ataxia, but unlike ocular, systemic adverse drug reactions are rare and occur mainly in patients with risk factors. In addition, six cases of abuse were found. The treatment with cyclopentolate is effective and safe in most cases; nevertheless, special care must be taken due to the potential severe ADRs that may occur, especially in susceptible patients like children, geriatrics, patients with neurological disorders or Down's syndrome, patients with a low blood level of pseudocholinesterase, users of substances with CNS effects, and patients with a history of drug addiction. The recommendations are avoiding the use of 2% cyclopentolate and instead employing solutions with lower concentrations, preferably with another mydriatic such as phenylephrine. Likewise, the occlusion of the nasolacrimal duct after instillation limits the drug's absorption, reducing the risk of systemic adverse events.
Collapse
Affiliation(s)
| | - Vanessa Orozco-Ceja
- Pharmacovigilance Department, Laboratorios Sophia, S.A. de C.V, Zapopan, Jalisco, México
| | | | | | | | | |
Collapse
|
2
|
Xu G, Huang S, Peng J, Gao X, Li M, Yu S, Liu Z, Qie P, Wang Y, Yu S, Liu S, Wen H, Su L, Li P, Guang B, Dong R, Liu J, Yang T. Targeting lipid metabolism in multiple myeloma cells: rational development of a synergistic strategy with proteasome inhibitors. Br J Pharmacol 2021; 178:4741-4757. [PMID: 34378191 DOI: 10.1111/bph.15653] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Revised: 07/05/2021] [Accepted: 07/12/2021] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND AND PURPOSE Aberrant lipid metabolism is now recognized as a key feature of cancer cells. Our initial research on mass spectrometry-based analysis of lipids in a multiple myeloma (MM) cell line showed a significant accumulation of lipids in MM cells after proteasome inhibition. This finding prompted us to hypothesize that MM cell survival depends on the maximal utilization of abnormally accumulated lipids. Therefore, we explored whether lipid metabolism-modulating agents would synergize with proteasome inhibitors (PIs). EXPERIMENTAL APPROACH The abnormal massive lipid accumulation in MM cells was detected using mass spectrometry. Cell viability and cell apoptosis were detected to assess the synergistic effect of lipid regulators and PIs. Otherwise, a novel stable derivative (FCE) of fenofibrate (FEN) was synthesized and used to treat MM cells in vitro and in vivo along with ixazomib. ChIP-seq, western blotting and RT-qPCR were performed to explore the potential mechanism underlying the increase in lipid levels in MM cells after proteasome inhibition. KEY RESULTS The accumulation of lipids in MM cells was induced by proteasome inhibition. Lipid-lowering drugs and MG-132 exerted a synergistic effect to kill MM cells. FCE showed significant synergistic activity in vitro and in vivo with ixazomib. The abnormal lipid accumulation in MM cells that was enhanced by proteasome inhibitors might be due to the elevated SREBP1/2 expression induced by ATF4. CONCLUSIONS AND IMPLICATIONS In summary, the results provide a proof of principle and rationale for the further clinical evaluation of the combination of lipid-modulating drugs with proteasome inhibitors.
Collapse
Affiliation(s)
- Gaojie Xu
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Sheng Huang
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Jian Peng
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Xiaofang Gao
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Minhui Li
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Sisi Yu
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China
| | - Zuofeng Liu
- Department of Hematology, The Third People's Hospital of Chengdu, Chengdu, Sichuan Province, China
| | - Pengfan Qie
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Yu Wang
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Siqi Yu
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Siyuan Liu
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Hu Wen
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Lijuan Su
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Ping Li
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Bin Guang
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China.,Chengdu Biobel Biotechnology Co., Ltd., Chengdu, Sichuan Province, China
| | - Renhan Dong
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China.,Chengdu Biobel Biotechnology Co., Ltd., Chengdu, Sichuan Province, China
| | - Jin Liu
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Tai Yang
- School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| |
Collapse
|
3
|
Nuijts RMMA, Mencucci R, Viaud-Quentric K, Elena PP, Olmière C, Behndig A. Ocular tolerance in rabbits after intracameral administration of a fixed combination of tropicamide, phenylephrine, and lidocaine with and without rinsing. J Cataract Refract Surg 2017; 43:673-679. [PMID: 28602331 DOI: 10.1016/j.jcrs.2017.03.025] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Revised: 02/21/2017] [Accepted: 03/06/2017] [Indexed: 11/17/2022]
Abstract
PURPOSE To evaluate the safety and tolerability of a single intracameral administration of a combined mydriatic (tropicamide and phenylephrine) and anesthetic (lidocaine) formulation (Mydrane) with or without rinsing. SETTING Iris Pharma, La Gaude, France. DESIGN Experimental study. METHODS Sixty pigmented rabbits received 100 μL or 200 μL of the combination product or a placebo (sodium chloride 0.9%) by intracameral injection. For the combination product, separate groups were included with and without rinsing after administration. From day 1 day to day 7, assessments included general clinical and ocular observations, pupil diameter measurements, corneal assessments, confocal microscopy, and electroretinography (ERG). Necropsy examinations were performed at study completion at day 8. RESULTS Rapid mydriasis, stable 24 minutes after injection and returning to baseline levels by day 1, was induced in all groups that received the combination mydriatic and anesthetic drug. Rinsing had no effect. The combination product induced no adverse effects on the anterior or posterior segment of the eye (ie, no increased corneal thickness and endothelial cell loss, no abnormalities in ERG). Slitlamp examination showed slightly increased anterior chamber inflammation with rinsing in both the study group and placebo group. This observation was not confirmed by aqueous flare examination. No toxic effects of the products were found on histological evaluation. CONCLUSION The combination mydriatic and anesthetic drug administered to pigmented rabbits as a single intracameral injection at volumes of 100 μL and 200 μL was well tolerated with no ocular adverse effects and no effect on the corneal endothelium.
Collapse
Affiliation(s)
- Rudy M M A Nuijts
- From Maastricht University Medical Center Maastricht (Nuijts), Maastricht, the Netherlands; Universita degli Studi di Firenze (Mencucci), Florence, Italy; Iris Pharma (Viaud-Quentric), La Gaude, and Laboratoires Théa (Olmière), Clermont-Ferrand, France; Umeå University Hospital (Behndig), Umeå, Sweden
| | - Rita Mencucci
- From Maastricht University Medical Center Maastricht (Nuijts), Maastricht, the Netherlands; Universita degli Studi di Firenze (Mencucci), Florence, Italy; Iris Pharma (Viaud-Quentric), La Gaude, and Laboratoires Théa (Olmière), Clermont-Ferrand, France; Umeå University Hospital (Behndig), Umeå, Sweden
| | - Karen Viaud-Quentric
- From Maastricht University Medical Center Maastricht (Nuijts), Maastricht, the Netherlands; Universita degli Studi di Firenze (Mencucci), Florence, Italy; Iris Pharma (Viaud-Quentric), La Gaude, and Laboratoires Théa (Olmière), Clermont-Ferrand, France; Umeå University Hospital (Behndig), Umeå, Sweden
| | - Pierre-Paul Elena
- From Maastricht University Medical Center Maastricht (Nuijts), Maastricht, the Netherlands; Universita degli Studi di Firenze (Mencucci), Florence, Italy; Iris Pharma (Viaud-Quentric), La Gaude, and Laboratoires Théa (Olmière), Clermont-Ferrand, France; Umeå University Hospital (Behndig), Umeå, Sweden
| | - Céline Olmière
- From Maastricht University Medical Center Maastricht (Nuijts), Maastricht, the Netherlands; Universita degli Studi di Firenze (Mencucci), Florence, Italy; Iris Pharma (Viaud-Quentric), La Gaude, and Laboratoires Théa (Olmière), Clermont-Ferrand, France; Umeå University Hospital (Behndig), Umeå, Sweden.
| | - Anders Behndig
- From Maastricht University Medical Center Maastricht (Nuijts), Maastricht, the Netherlands; Universita degli Studi di Firenze (Mencucci), Florence, Italy; Iris Pharma (Viaud-Quentric), La Gaude, and Laboratoires Théa (Olmière), Clermont-Ferrand, France; Umeå University Hospital (Behndig), Umeå, Sweden
| |
Collapse
|
4
|
Casal-Dominguez JJ, Furkert D, Ostovar M, Teintang L, Clark MJ, Traynor JR, Husbands SM, Bailey SJ. Characterization of BU09059: a novel potent selective κ-receptor antagonist. ACS Chem Neurosci 2014; 5:177-84. [PMID: 24410326 DOI: 10.1021/cn4001507] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Kappa-opioid receptor (κ) antagonists are potential therapeutic agents for a range of psychiatric disorders. The feasibility of developing κ-antagonists has been limited by the pharmacodynamic properties of prototypic κ-selective antagonists; that is, they inhibit receptor signaling for weeks after a single administration. To address this issue, novel trans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl) piperidine derivatives, based on JDTic, were designed using soft-drug principles. The aim was to determine if the phenylpiperidine-based series of κ-antagonists was amenable to incorporation of a potentially metabolically labile group, while retaining good affinity and selectivity for the κ-receptor. Opioid receptor binding affinity and selectivity of three novel compounds (BU09057, BU09058, and BU09059) were tested. BU09059, which most closely resembles JDTic, had nanomolar affinity for the κ-receptor, with 15-fold and 616-fold selectivity over μ- and δ-receptors, respectively. In isolated tissues, BU09059 was a potent and selective κ-antagonist (pA2 8.62) compared with BU09057 (pA2 6.87) and BU09058 (pA2 6.76) which were not κ-selective. In vivo, BU09059 (3 and 10 mg/kg) significantly blocked U50,488-induced antinociception and was as potent as, but shorter acting than, the prototypic selective κ-antagonist norBNI. These data show that a new JDTic analogue, BU09059, retains high affinity and selectivity for the κ-receptor and has a shorter duration of κ-antagonist action in vivo.
Collapse
Affiliation(s)
| | - Daniel Furkert
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, United Kingdom
| | - Mehrnoosh Ostovar
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, United Kingdom
| | - Linnea Teintang
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, United Kingdom
| | - Mary J. Clark
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - John R. Traynor
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Stephen. M. Husbands
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, United Kingdom
| | - Sarah J. Bailey
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, United Kingdom
| |
Collapse
|
5
|
Ji F, Wu W, Dai X, Mori N, Wu J, Buchwald P, Bodor N. Synthesis and pharmacological effects of new, N-substituted soft anticholinergics based on glycopyrrolate. J Pharm Pharmacol 2010; 57:1427-35. [PMID: 16259775 DOI: 10.1211/jpp.57.11.0008] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Abstract
To reduce the possibility of systemic side-effects in locally administered anticholinergics, two new N-substituted glycopyrrolate analogues designed using soft drug design approaches have been synthesized and evaluated in vitro and in vivo. Because stereospecificity is known to be important at muscarinic receptors, the new compounds SGM and SGE also have been prepared as their pure 2R isomers, 2R-SGM and 2R-SGE, by starting from optically pure (-)-cyclopentylmandelic acid, and the corresponding isomers were indeed found to be more active. The new soft glycopyrrolates were chemically more stable under acidic conditions, and the ethyl esters SGE were more stable than the methyl esters SGM. The new compounds were also found to be quite susceptible to extrahepatic metabolism, having half-lives of 20–30 min in rat plasma (in vitro), consistent with their soft nature. Binding studies at human muscarinic receptors (M1−M4) and guinea-pig ileum assays found 2R-SGM and 2R-SGE to have potencies somewhat less than, but close to, those of glycopyrrolate and N-methylscopolamine. They caused pupil dilation in rabbit eyes, but their mydriatic effects lasted for considerably less time than that of glycopyrrolate, and they did not induce dilation of the pupil in the contralateral, water-treated eyes, indicating that, in agreement with their soft nature, they are locally active, but safe and with a low potential to cause systemic side-effects.
Collapse
Affiliation(s)
- F Ji
- Center for Drug Discovery, College of Pharmacy, University of Florida, PO Box 100497, Gainesville, FL 32610-0497, USA
| | | | | | | | | | | | | |
Collapse
|
6
|
Wu WM, Buchwald P, Mori N, Ji F, Wu J, Bodor N. Pharmacokinetic and Pharmacodynamic Evaluations of the Zwitterionic Metabolite of a New Series of N-Substituted Soft Anticholinergics. Pharm Res 2005; 22:2035-44. [PMID: 16170596 DOI: 10.1007/s11095-005-8174-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2005] [Accepted: 08/16/2005] [Indexed: 10/25/2022]
Abstract
PURPOSE This study was conducted to evaluate the zwitterionic common metabolite of a novel series of N-substituted soft analogs of glycopyrrolate both as racemates and as 2R isomers. METHODS Activities were assessed using both in vitro (receptor binding assay, guinea pig ileum pA2 assay) and in vivo techniques (rabbit mydriatic response, rat cardiac effects). Pharmacokinetic characterizations in rats were also performed. RESULTS The metabolite was highly water-soluble and very stable in buffer solutions as well as in rat biological media. Following i.v. administration in rats, it was very rapidly eliminated, mainly through renal excretion with a half-life of about 10 min. Receptor binding and guinea pig ileum assays indicated this metabolite as more than 1 order of magnitude less active than its parent soft drugs or glycopyrrolate. Moderate M3/M2 muscarinic receptor subtype selectivity was observed, further reducing the likelihood of cardiac side effects. The metabolite showed to some extent mydriatic effect and protective effect against carbachol-induced bradycardia, but of much shorter durations than glycopyrrolate; it had, however, no effect on resting heart rate. CONCLUSIONS N-Substituted zwitterionic metabolites retain some, but only considerably reduced activity of their parent quaternary ammonium ester soft anticholinergic drugs, and they are very rapidly eliminated from the systemic circulation. They are suitable for their assigned role within the framework of inactive metabolite-based soft anticholinergic design.
Collapse
MESH Headings
- Administration, Topical
- Animals
- Bradycardia/chemically induced
- Bradycardia/prevention & control
- Carbachol
- Chemical Phenomena
- Chemistry, Physical
- Cholinergic Antagonists/chemistry
- Cholinergic Antagonists/pharmacokinetics
- Cholinergic Antagonists/pharmacology
- Chromatography, High Pressure Liquid
- Guinea Pigs
- Heart Rate/drug effects
- Ileum/drug effects
- Ileum/metabolism
- In Vitro Techniques
- Injections, Intravenous
- Liver/metabolism
- Lung/metabolism
- Male
- Models, Molecular
- Muscarinic Agonists
- Muscle Contraction/drug effects
- Muscle, Smooth/drug effects
- Mydriatics
- Rabbits
- Rats
- Rats, Sprague-Dawley
- Receptors, Muscarinic/drug effects
- Receptors, Muscarinic/metabolism
- Solubility
- Solutions
- Spectrophotometry, Ultraviolet
Collapse
Affiliation(s)
- Whei-Mei Wu
- Center for Drug Discovery, College of Pharmacy, University of Florida, Gainesville, Florida, USA
| | | | | | | | | | | |
Collapse
|
7
|
Huang F, Browne CE, Wu WM, Juhász A, Ji F, Bodor N. Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics. Pharm Res 2004; 20:1681-9. [PMID: 14620526 DOI: 10.1023/a:1026160023030] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
PURPOSE To design and evaluate a new class of soft anticholinergics with subtype selectivity. METHODS A new class of soft anticholinergics was designed based on the "inactive metabolite" approach. Four compounds were synthesized. The potency and soft nature of the compounds were evaluated by receptor binding, cardiac, and mydriatic studies. Stability and pharmacokinetic studies were also performed on these newly synthesized soft anticholinergics. RESULTS Receptor binding studies of the soft anticholinergics on cloned muscarinic receptors indicated pKi values in the range of 7.5 to 8.9. Two compounds, 9a and 13a, of the series showed muscarinic subtype receptor selectivity (M3/M2). In mydriatic studies, 13a and 13b showed shorter duration of action in the treated eyes than tropicamide. In the control eyes, significant dilation of pupils was found only in rabbits treated with atropine and tropicamide, indicating that the soft anticholinergics lack systemic effects because of their facile hydrolytic deactivation. Consistent with their soft nature, this new class of soft anticholinergics displayed much shorter cardiovascular effects in the carbachol-induced bradycardia (10 to 15 min) in rats than atropine (> 60 min). Stability and pharmacokinetic studies suggested that the new soft anticholinergics were rapidly eliminated from plasma (systemic circulation) after i.v. administration. CONCLUSIONS A new class of anticholinergics was designed and synthesized, and the PK/PD evaluation confirmed they were potent "soft" anticholinergics; two of them showed muscarinic receptor subtype selectivity (M3/M2).
Collapse
Affiliation(s)
- Fenglei Huang
- Center for Drug Discovery, College of Pharmacy, University of Florida, Gainesville, Florida 32610, USA
| | | | | | | | | | | |
Collapse
|
8
|
Huang F, Buchwald P, Browne CE, Farag HH, Wu WM, Ji F, Hochhaus G, Bodor N. Receptor binding studies of soft anticholinergic agents. AAPS PHARMSCI 2001; 3:E30. [PMID: 12049493 PMCID: PMC2751219 DOI: 10.1208/ps030430] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2001] [Accepted: 11/13/2001] [Indexed: 12/29/2022]
Abstract
Receptor binding studies were performed on 24 soft anticholinergic agents and 5 conventional anticholinergic agents using 4 cloned human muscarinic receptor subtypes. The measured pK(i) values of the soft anticholinergic agents ranged from 6.5 to 9.5, with the majority being in the range of 7.5 to 8.5. Strong correlation was observed between the pK(i) s determined here and the pA 2 values measured earlier in guinea pig ileum contraction assays. The corresponding correlation coefficients (r2) were 0.80, 0.73, 0.81, and 0.78 for pK(i) (m1), pK(i) (m2), pK(i) (m3), and pK(i) (m4), respectively. Quantitative structure-activity relationship (QSAR) studies were also performed, and good characterization could be obtained for the soft anticholinergics containing at least 1 tropine moiety in their structure. For these compounds, the potency as measured by the pK i values was found to be related to geometric, electronic, and lipophilicity descriptors. A linear regression equation using ovality (O(e)), dipole moment (D), and a calculated log octanol-water partition coefficient (QLogP) gave reasonably good descriptions (r = 0.88) for the pK(i) (m3) values.
Collapse
Affiliation(s)
- Fenglei Huang
- Center for Drug Discovery, College of Pharmacy, University of Florida, 32610-0497 Gainesville, FL
| | - Peter Buchwald
- Center for Drug Discovery, College of Pharmacy, University of Florida, 32610-0497 Gainesville, FL
| | - Clinton E. Browne
- Center for Drug Discovery, College of Pharmacy, University of Florida, 32610-0497 Gainesville, FL
| | - Hassan H. Farag
- Center for Drug Discovery, College of Pharmacy, University of Florida, 32610-0497 Gainesville, FL
| | - Wnei-Mei Wu
- Center for Drug Discovery, College of Pharmacy, University of Florida, 32610-0497 Gainesville, FL
| | - Fubao Ji
- Center for Drug Discovery, College of Pharmacy, University of Florida, 32610-0497 Gainesville, FL
| | - Guenther Hochhaus
- Center for Drug Discovery, College of Pharmacy, University of Florida, 32610-0497 Gainesville, FL
| | - Nicholas Bodor
- Center for Drug Discovery, College of Pharmacy, University of Florida, 32610-0497 Gainesville, FL
| |
Collapse
|
9
|
|
10
|
Abstract
Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metabolism considerations into the drug design process. Soft drugs are new therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their therapeutic effect. Hence, they are obtained by building into the molecule, in addition to the activity, the most desired way in which the molecule is to be deactivated and detoxified. In an attempt to systematize and summarize the related work done in a number of laboratories, including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts. A number of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles. Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, beta-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others. Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compounds used in the same field.
Collapse
Affiliation(s)
- N Bodor
- Center for Drug Discovery, University of Florida, Health Science Center, P.O. Box 100497, Gainesville, Florida 32610-0497, USA.
| | | |
Collapse
|
11
|
The Role of Computational Techniques in Retrometabolic Drug Design Strategies. ACTA ACUST UNITED AC 1999. [DOI: 10.1016/s1380-7323(99)80090-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/26/2023]
|
12
|
|
13
|
|
14
|
Analytical challenges in chemical-enzymatic drug targeting. Adv Drug Deliv Rev 1994. [DOI: 10.1016/0169-409x(94)90047-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
15
|
|
16
|
Hammer R, Kumar G. Soft anticholinergics. Adv Drug Deliv Rev 1994. [DOI: 10.1016/0169-409x(94)90045-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Bodor N. Designing safer ophthalmic drugs by soft drug approaches. JOURNAL OF OCULAR PHARMACOLOGY 1994; 10:3-15. [PMID: 7911503 DOI: 10.1089/jop.1994.10.3] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
There are two major novel metabolism-based drug design concepts which have significant advantages when used in the design of safe, specific ophthalmic drugs. One is based on predictable enzymatic activation processes by enzymes found exclusively or preferentially at the site of action--in this case, within the eye, primarily in the iris-ciliary body. The second major retrometabolic design technique involves soft drug approaches. Among the various soft drug design strategies, it was found that the "inactive metabolite" and the "soft analog" approaches are the most useful for designing safe and selective ophthalmic drugs. In the first case, the design process starts with a known (or predicted) inactive metabolite (Mi) of the drug (D). This Mi is then structurally modified in the "chemical activation" stage to the soft drug (SD), which is isosteric and/or isoelectronic with D to produce activity at the target receptors, similar to that of D. By design, however, SD is also subject to a facile, predictable (generally hydrolytic) metabolism leading in one step to the starting inactive Mi. As this deactivation takes places everywhere in the body, the desired activities are produced virtually exclusively at the target site at or near the place of application. Successful use of this general concept has led to soft beta-blockers as safe antiglaucoma agents, soft anticholinergics as short acting mydriatic agents, and soft corticosteroids as a type of novel, safe anti-inflammatory agents, which due to their unique design, do not elevate intraocular pressure IOP and do not produce other systemic and local side effects.
Collapse
Affiliation(s)
- N Bodor
- Center for Drug Discovery, College of Pharmacy, University of Florida, Gainesville
| |
Collapse
|
18
|
Kumar G, Huang MJ, Hammer R, Bodor N. Soft drugs. 17: Quantitative structure-activity relationships of soft anticholinergics based on methatropine and methscopolamine. J Pharm Sci 1994; 83:117-8. [PMID: 8138901 DOI: 10.1002/jps.2600830129] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
19
|
Kumar GN, Hammer RH, Bodor NS. Soft drugs--XVI. Design, evaluation and transdermal penetration of novel soft anticholinergics based on methatropine. Bioorg Med Chem 1993; 1:327-32. [PMID: 8081862 DOI: 10.1016/s0968-0896(00)82138-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Atropine has been reported to produce unwanted systemic side effects on topical administration into the eye. The same problem could arise when atropine is used topically as a suppressant of eccrine sweating. In this study, the principles of soft drug design were applied to methatropine. A hypothetical carboxylate metabolite of methatropine was reactivated by esterification with cyclic and alicyclic alcohols to yield a series of compounds (3a-g). In vitro evaluation by guinea pig ileum assay indicated that the compounds are potent anticholinergics and the lead carboxylate metabolite is about 60 times less potent than the most active compound of the series. The activity was found to decrease with the increasing side chain length. The n-octanol/water partition coefficients were found to be directly dependent on the chain length for the compounds made with straight chain alcohols. The transdermal permeability coefficients across the hairless mice skin were found to be directly dependent on the partition coefficients. The soft drugs are found to metabolize extensively during the penetration process compared to the unmetabolizable nature of methatropine. The soft drugs reported in this study will probably be able to elicit a local action at the site of application but will probably be metabolized rapidly in the systemic circulation, thereby avoiding the systemic side effects with a consequent increase in the therapeutic index.
Collapse
Affiliation(s)
- G N Kumar
- Center for Drug Discovery, JHMHC, College of Pharmacy, University of Florida, 32610
| | | | | |
Collapse
|
20
|
Hammer RH, Gunes E, Kumar GN, Wu WM, Srinivasan V, Bodor NS. Soft drugs--XIV. Synthesis and anticholinergic activity of soft phenylsuccinic analogs of methatropine. Bioorg Med Chem 1993; 1:183-7. [PMID: 8081850 DOI: 10.1016/s0968-0896(00)82119-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Three soft drug analogs and a metabolite of methatropine based on phenylsuccinic structural moiety were synthesized and tested for activity. In an in vivo assay, the soft drugs were found to be two orders of magnitude less potent than methatropine while the carboxylate metabolite was found to be one order of magnitude less potent than the soft drugs. A structural isomer of compound 4a was found to be less potent. All the soft drugs tested elicited shorter durations of mydriatic action in rabbit eyes compared to atropine. The untreated eye was dilated in the atropine treated animals while no dilation occurred in the soft drug treated animals indicating facile systemic metabolism of the soft drugs to inactive moieties, possibly the carboxylate metabolite. In in vitro stability studies, the soft drugs have been found to be more hydrolytically labile than atropine. The shorter duration of mydriatic action of compound 4a coupled with increased hydrolytic lability make this a candidate for further study.
Collapse
Affiliation(s)
- R H Hammer
- Center for Drug Discovery, College of Pharmacy, University of Florida, Gainesville 32610
| | | | | | | | | | | |
Collapse
|
21
|
Abstract
Due to absorption several ocularly applied medications give rise to systemic side-effects. The problem of systemic drug absorption should be taken into account in designing ocular drug and dosage forms so that oculospecificity of the medications is optimized. In this review we summarize the current knowledge about the systemic absorption of ocularly applied topical drugs. Special emphasis is directed to the methods that can be used to minimize systemic absorption and increase the oculospecificity of drugs, e.g., reducing volume and increasing viscosity of eyedrops, controlling drug release from depot preparations, prodrug-derivatization, and addition of vasoconstrictive agents.
Collapse
Affiliation(s)
- A Urtti
- Department of Pharmaceutical Technology, University of Kuopio, Finland
| | | |
Collapse
|